The 10 Types of ER Patients .


You’re sitting in the waiting room, icing your sore ankle. The teenager to your right is moaning and clutching his belly. The woman to your left is coughing into her mask. A stretcher rolls by with a man yelling at the top of his lungs. An ambulance arrives. You see paramedics performing CPR. You wonder, with all this chaos around you, how can you make sure that your emergency room doctor will address your concerns? Along with primary care physicians, we emergency providers are the frontlines of medical care. We see people with every imaginable issue. Some ER patients are critically ill—from trauma, heart attack, or severe infection. These patients will get seen immediately and have the full focus of ER staff. Other patients are not critically ill but still have needs that must be tended to. As an emergency physician and patient advocate, I’ve met many patients who are frustrated by their medical care. I wish I could have given them advice before they came to the ER. I see some of the same missed opportunities and miscommunications again and again. Categorizing the clusters of difficulties can help to identify and fix the problems. Here are my suggestions for 10 types of ER patients. I don’t intend to stereotype or imply that every patient falls into one of these categories. If you recognize yourself in one of these categories, you may benefit from some guidance to help us best help you. No. 1: The Repeat Customer. Often, ER docs will see a patient who’s had headaches for 10 years or foot pain for even longer. If you have a chronic, ongoing issue, explain why today is the day you came to the ER. Help us understand why you’re here. Maybe your symptoms have changed. Perhaps your sister just got diagnosed with cancer and you’re worried. Please tell us the truth. If there is truly nothing new and you have a primary care physician, please consider making an appointment with her. We can take care of acute pain, but you will need someone to follow you for ongoing medical problems. No. 2: The Second-Opinion Seeker. You’ve had months of troublesome symptoms. Nobody—not your primary care physician, not the five specialists you’ve seen—has given you a satisfactory answer. We understand that you’re concerned, but it’s unlikely that in the ER, with limited time and resources, we can give you the in-depth investigation you deserve. Ask your regular doctor for referrals and further testing. Keep in mind that we have finite resources; if you’re in our emergency MRI for your chronic knee pain, that means the patient with the possible stroke needs to wait. No. 3: The Googler. The Internet can be a powerful tool for empowering patients, but please use it responsibly. Looking up your symptoms yourself might turn up that you have a brain tumor when you have food poisoning or that you are pregnant when you have belly pain (and you’re a man). Use the Internet to help you understand your diagnosis and treatment and to come up with questions—not to diagnose yourself. No. 4: The “Pain All Over” Patient. We call it the “positive review of systems” when you say yes to everything we ask. Headache? Chest pain? Shortness of breath? Fatigue? Muscle aches? Yes, yes, of course, yes. Some illnesses really affect many parts of the your body, but more often than not, patients will say yes to convince us they are ill. We know you aren’t well, so tell us the truth. (If you don’t, you run the risk of undergoing unnecessary testing.) If everything hurts, try to tell us your story. When did you last feel normal and well? What happened then? And please don’t exaggerate. If you say that your pain is 15 out of 10, but you’re eating lunch and texting on your iPhone, it’s hard for us to calibrate your symptoms. No. 5: The “Totally Healthy” Person. I can’t tell you how often a patient will tell me he is healthy with no medical problems, then mention to his nurse that he gets insulin shots and takes “some white and blue pills.” Please give us the full information about your health. Few visits to the ER are truly such an emergency that you don’t have time to prepare in advance. Carry a card with you of all your medical conditions, past surgeries, allergies, and current medications and dosages. Don’t forget vitamins and herbal supplements. Let your doctor know you’re coming; she can call in and let us know, or she might say you can see her that day instead of going to the ER. No. 6: The Forgetter. Often, I’ll ask patients what brought them to the ER, and they’ll look at me blankly. “I don’t know,” they’ll say. Going to the ER is stressful, especially if you’re ill and already not feeling well. While you’re waiting for the doctor, write down your symptoms and key concerns. Bring a family member or friend with you who can help you speak up. There is limited time to see the doctor, so you have to make use of that time and tell us why you are here. If you brought a loved one to be seen, stay with the person—this isn’t the time to go shopping and leave granny alone in the waiting room. No. 7: The Narcotic Seeker. This is the patient who says he has chronic pain and is out of his narcotic medications; for some reason, he cannot contact his primary care physician, and his pills have all been “stolen.” The United States has an epidemic of prescription drug abuse, and we in the ER inadvertently become detectives. We want to be careful to identify patients who have real pain and real need, but we also don’t want to feed addiction and even criminal behavior of those who abuse the system. If you have a real need, explain what happened and why you cannot see your regular doctor. If it’s a different pain than usual, tell us clearly—perhaps there is an underlying new problem that we have to investigate. No. 8: The Small Talker. We want to talk to you; we really do. Actually, the greatest pleasure of my work is getting to know people, and I would love to sit and chat. Unfortunately, there are 20 other patients waiting to see me, and my job is to help you and them. So please tell me about your health, and ask me as much as you want about that. I don’t want to be rude, and I appreciate your interest in me, but please help me help you by focusing on your health. No. 9: The Yeller. You’ve been waiting for hours. You’re in a tiny room; the TV doesn’t work. We are sorry about this; we truly are. Our ER may have 50—100—patients in it, and we have to take care of everyone in order of severity. Screaming and shouting doesn’t help, nor does threatening to call your lawyer, the hospital CEO, or the local news station. Please be assured that we are working very hard and are trying to take care of you as quickly and as well as possible. If something has changed and you are feeling worse, please let us know. If you want to help the ER improve, there are often opportunities to do so by joining patient advisory committees. No. 10: The Apologizer. “I’m so sorry to come in for this. You have a lot of other patients who look worse than me.” It’s possible that other patients may be sicker, but you came because you weren’t feeling well. Help us understand what prompted you to come in today. We know it’s hard to know when it’s necessary to come to the ER and when it’s not. And there’s no need to feel sorry for us. We chose this job because we want to treat all patients, regardless of who they are and what conditions ail them. We are proud to have the privilege of caring for you.

[​IMG]

IE, once king of browsers, to be phased out


Microsoft is developing a new, streamlined web browser that will replace Internet Explorer, according to reports, in an apparent attempt to move towards other popular browsers like Chrome and Firefox.

The browser, codenamed Spartan, is set to be shown off on January 21 when Microsoft demonstrates its new Windows 10 operating system (OS), according to people close to the firm.

The new app could also help Microsoft distance itself from users’ bad memories of old versions of IE. In the past the company has considered changing the name to separate the current browser from “negative perceptions that no longer reflect reality”, according to developers.

The browser, codenamed Spartan, is set to be shown off on January 21 when Microsoft demonstrates its new Windows 10 operating system (OS), according to people close to the firm. But it might not be ready for release when the early version of the software launches the same month. It will be available for both desktop and mobile versions of the operating system, according to ZDNet.

Though the new browser will be the default one in future versions of the OS, Windows 10 will ship with a new and backwards-compatible version of Internet Explorer, IE 12, too. The new browser will still use many of the same technologies as Explorer, but will have a stripped down look and feel, and will support extensions.

While the company has long been thought to be planning an overhaul of its browser for the new OS, it was previously expected that would come as an update to IE rather than as a separate app.

Thomas Nigro, a developer on video app VLC and a Microsoft student partner, was one of the first people to mention the new browser.

IE was released in 1995 and has since gone through 11 versions. It initially dominated the market, but competitors like Firefox and Chrome have steadily taken its share.

Estimates of its use put it around a quarter and a half of all browsing.

Never Too Late: 5 Bad Habits You Should Still Quit


The U.S. Centers for Disease Control and Prevention says avoidable behaviors like cigarette use, poor diet and lack of exercise are the underlying cause of half of the deaths in the United States. A new study finds it’s never too late to gain health benefits by knocking off such bad habits.

During a five-year study, researchers tested the walking speeds of 2,000 people who either smoke, were smokers, or had never smoked. Current smokers walked more slowly than those who had stopped. The findings will be presented next week at the American Geriatrics Society’s Annual Meeting.

The results suggest that even at an older age, changing bad habits such as smoking can positively impact a senior’s health later in life. Study leader Alison Moore of the American Geriatrics Society this week suggested five bad habits that should be halted if you wish to live longer.

http://www.livescience.com/14389-bad-habits.html?adbid=10152466250986761&adbpl=fb&adbpr=30478646760&cmpid=514627_20141231_37496997

Distinguishing Grief, Complicated Grief, and Depression


Editor’s Note: Depression, grief, and complicated grief can be difficult to distinguish from one another. However, a study[1]recently published in JAMA Psychiatry—the first randomized trial to explore the treatment of complicated grief (CG) in an elderly population—emphasizes how important it is to recognize when grieving patients are also suffering from comorbid psychopathology, so that appropriate care can be delivered. Medscape contributor Ronald W. Pies, MD, professor of psychiatry at SUNY Upstate Medical University in Syracuse, New York, recently moderated an email discussion between lead author M. Katherine Shear, MD, program director for Columbia University’s Center for Complicated Grief, and Sidney Zisook, MD, distinguished professor and director, Department of Psychiatry at the University of California San Diego, La Jolla, California, on what complicated grief is, how to treat it, and how to distinguish it from grief and depression.

Depression vs Grief vs Complicated Grief

Dr Pies: I’m delighted to have my colleagues, Dr Sid Zisook and Dr Kathy Shear, join me in a discussion of grief, depression, and some of the controversies surrounding these topics.

Sid and Kathy, as we know, the concepts of grief, complicated grief, and depression are sometimes tough for clinicians to sort out. This is especially true in the context of recent bereavement: that is, following the death of a loved one or significant other. Sometimes our colleagues in primary care—and in psychiatry, too—find it hard to tell whether a patient who has just suffered the death of a loved one is experiencing grief or depression, both, or neither. Unfortunately, these terms are often used in confusing ways, both in the popular media and in some of the professional literature.

So, to get the ball rolling, can we provide some brief, basic definitions or descriptions of the terms “grief,” “complicated grief,” and “depression”?

Dr Zisook: “Depression” is a broadly used term for the self-limiting and generally benign everyday blues that we all experience from time to time, as well as a catch-all for a group of serious, often quite malignant mental illnesses, herein grouped under the rubric “major depression.” The latter, in turn, encompasses a group of important clinical conditions: major depressive episodes (MDEs) seen in bipolar mood disorders, major depressive disorder (MDD, or “unipolar” depression); and persistent depressive disorder, which may or may not have fewer or less intense symptoms than MDD, but is marked by its persistence (at least 2 years’ duration).

Each of these clinical conditions are themselves heterogeneous, comprising a spectrum of severity from relatively mild to quite severe. And they may (but not necessarily) be associated with anxious, mixed, melancholic, atypical, or psychotic features, and may be in full bloom or in partial or full remission.

To help clinicians differentiate the nonclinical type of depression—sadness or the blues—from the clinical conditions, it is important to remember that none of these clinical conditions should be diagnosed absent three key characteristics:

Severity (at least five of the characteristic symptoms);

Duration (most of the day, nearly every day, for at least 2 weeks); and

Pathology (clinically significant distress or impairment).

In keeping with the acknowledgment in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), that classification of mental disorders is a work in progress, and that the current classification system is intended to serve as a “practical, functional, and flexible guide for organizing information that can aid in the accurate diagnosis and treatment of mental disorders,” we favor also adding clinical judgment and caution to the diagnostic menu.

Thus, if a person meets criteria for one of the clinical conditions, but it is a first episode and relatively mild (eg, only five or six symptoms are met and these do not include feelings of worthlessness or suicidal ideation), brief (less than 1 or 2 months) and only minimally impairing, it may make sense to delay making a formal or definitive diagnosis while more information is gathered and a tincture of time is allowed its due.

Just as it is important not to overdiagnose the blues of everyday life as major depression, it is every bit as vital not to overlook major depression when it is there. No disorder is more painful or has a more profound effect on the way a person relates to others, feels about themselves or their worth as a human being, functions in everyday activities, or maintains hope of a better future.

Here, I think a quote from Infinite Jest, by David Foster Wallace, beautifully describes severe major depression:

It is a level of psychic pain wholly incompatible with human life as we know it. It is a sense of radical and thoroughgoing evil not just as a feature but as the essence of conscious existence. It is a sense of poisoning that pervades the self at the self’s most elementary levels. It is a nausea of the cells and soul.

Sometimes major depression seems to occur out of the blue, with no warning; sometimes its onset is gradual and almost unnoticeable; and sometimes it seems to be brought on, or intensified, by stressful life events, such as the death of a loved one. When that happens, a reverberating cycle sets in: The depression increases the stress, intensifies the grief, and may even interfere with grief’s resolution, setting the stage for a condition we call “complicated grief.”

Whether or not triggered by adversity, major depression tends to be both chronic (at least 20% of all episodes last 2 or more years) and recurrent (at least 90% of acute episodes recur). In its more severe forms, the sufferer is withdrawn and inconsolable, and ongoing life may feel untenable. In short, it is a miserable state.

President Abraham Lincoln said of being depressed:

I am now the most miserable man living. If what I feel were equally distributed to the whole human family, there would not be one cheerful face on the earth. Whether I shall ever be better I cannot tell; I awfully forebode I shall not. To remain as I am is impossible; I must die or be better, it appears to me.

In such a state, it is no surprise that thoughts of death or dying are core features of major depression and that suicide is an all-too-frequent tragic outcome, especially when the depression is unrecognized or untreated.

Treatments and Terminology

Dr Pies: And yet, as bad as the illness is, we have effective treatments for major depression; wouldn’t you agree, Sid?

Dr Zisook: Although treatments are imperfect—and there is ample room for better, more rapidly acting, safer, and more sustainable therapies—there is strong evidence that both antidepressant medications and depression-focused psychotherapies work. They reduce symptoms, enhance functioning, improve well-being, reduce suicide risk, and can reduce relapse and recurrence. For many individuals with major depression, combining antidepressants with psychotherapy is more effective than either alone.

There also is a role for exercise, light, good nutrition, and a host of other health-promoting behaviors, but these may become feasible only after the darkest periods begin to lift.

For those who have dwelt in depression’s dark wood…their return from the abyss is not unlike the ascent of the poet, trudging upward and upward out of hell’s black depths and at last emerging into what he saw as “the shining world.”

—William Styron, Darkness Visible

Dr Shear: Terminology is used inconsistently, so I will start by defining how we use key terms.

“Bereavement” is the situation of having experienced the death of someone close, not the response to the loss. “Grief” is the response to loss, not simply an emotion. The word “grief” is a simple shorthand for a complex, multifaceted experience that changes over time and varies from loss to loss. Grief is an automatic reaction, presumably guided by brain circuitry activated in response to a world suddenly, profoundly, and irrevocably altered by a loved one’s death.

At any given time, grief symptoms are a manifestation of ongoing psychobiological processes as modified by an evolving process of adaptation. Adapting to an important loss often entails reevaluation of one’s self-concept, and revising expectations and predictions of self and others, especially the deceased. Adaptation entails understanding the meaning of the finality and consequences of the loss and re-envisioning life goals and plans. As adaptation progresses, the frequency and intensity of grief symptoms attenuate.

Death is permanent, and so too is the response to the loss, though the manifestations of grief usually evolve and change over time. Grief can be considered as the form love takes when someone we lose someone we love. Like other forms of love, grief can be an avenue for personal change and growth.

Dr Pies: Kathy, what about the notion that people can and should “get over” grief?

Dr Shear: As Wortman and Silver[2] have argued, return to a prior state after a significant loss does not occur.They suggest that the idea of resolving grief is one of a number of common misconceptions not supported in survey studies of bereaved people. Another is the idea that successful adaptation means “letting go” or “saying goodbye” in order to “move on.”

Another misconception is the belief that experiencing and expressing strong emotions is the key to successful adaptation and that those who do not experience and express their emotions right after someone dies will pay later, or the corollaries of this—that the more intense a person’s emotions, the more effectively she or he is grieving and that once you have grieved effectively, you never have to grieve again.

Many clinicians believe that problems with grief are seen primarily in people who have an ambivalent relationship to the person who died. However, complicated grief is seen primarily in people who have enjoyed a very rewarding and loving relationship with the deceased.

Acute grief is the initial response to a painful loss that usually entails painful emotions; a sense of disbelief about the finality of the loss; preoccupation with thoughts, images, and memories of the deceased; and an inclination to social withdrawal. Longing, yearning, and sorrow are the most prominent emotions, often accompanied by a sense of disbelief even though the bereaved person knows that their loved one has died.

As time passes, the disbelief wanes; acute grief is reshaped, and its dominance subsides. As the finality and consequences of the loss are understood, grief is integrated into memory systems, emotional reactivity (both positive and negative) to reminders of the deceased is extinguished, and ways are discovered to use this relationship to foster continued psychological growth. Though grief is more than a feeling state, emotions form an important component of the response to bereavement.

Dr Pies: What, then, characterizes the person’s emotions in grief?

Dr Shear: Grief is not a single emotion, but rather contains a compendium of emotions, both negative and positive. Yearning and sorrow are the emotions that define grief. In addition, almost everyone experiences some anxiety, guilt, anger, or shame in response to a significant loss.

Most grieving people are anxious about the meaning of the loss, the experience of grief, or the shape of the future without their deceased loved one. Some people are afraid that they will never stop feeling wrenching pain, anxious about whether they can ever be happy again, or whether they can ever feel comfortable with themselves without the person they lost.

Many bereaved people experience some remorse or guilt about how they treated their loved one. Many feel some survivor guilt because they get to live and enjoy life when the person they loved can no longer do this.

Anger is also common. It is easy to feel cheated, to think it is unfair that the person died, or that someone failed in caring for the person who died. Sometimes anger is directed toward the person who died.

Grief creates feelings of extreme vulnerability, and people who pride themselves on being strong and capable can feel ashamed of the weakness that accompanies grief. People who value emotional control might be ashamed of uncontainable anguish.

Sometimes people also feel guilt or shame about having positive emotions. However, grief usually contains positive feelings interspersed with the negative ones, even in the early period of bereavement. Susan Folkman and her colleagues[3] found that bereaved people reported positive emotions as frequently as negative ones as early as 1 month after the death of someone very close. It feels good to recall happy memories, tell funny anecdotes, feel pride in honoring the person who died, or feel warmth in recollecting closeness to a loved one.

If the person who died was ill and burdensome, it is very natural to feel relief when they die. People might feel relief after the death of a person who was difficult to live with.

In addition to evoking strong emotions, bereavement presents major cognitive and behavioral challenges. Bereaved people need to change the ways in which they think about themselves, other people, and the world at large. Behavioral changes may be needed to achieve new roles or to form new relationships

Overall, many complex and varying emotional, cognitive, and behavioral changes are entailed in making the adaptation needed to come to terms with the loss and to re-envision the future after bereavement.

Coming to Terms With Loss

Dr Pies: Can you say what helps the grieving person adapt and come to terms with the loss?

Dr Shear: Adaptation is largely a learning process. Bereaved people need to assimilate information about the finality and consequences of the loss into long-term memory and learn new ways to envision their own lives without the deceased person.

The process of adaptation to a death has been described by Bowlby[4] as one in which we must change a mental model, and he points out that such a change is always resisted. Bowlby asserts that our minds mercifully move toward and away from acknowledging the painful reality, providing bouts of grief interspersed with periods of respite. In other words, adaptation typically progresses in fits and starts, in which we oscillate between confronting and reflecting on painful information about the loss, and then setting it aside. Stroebe and Schut[5] point out that loss brings dual coping challenges related to dealing with the loss on the one hand, and restoring a meaningful life on the other.

Different feelings associated with acute grief can guide and motivate changes that help people adjust to the death. At the same time, preoccupation with the person who died helps weave into adaptation ways to stay connected to the person who died, and to feel their presence as the bereaved begin to engage in their own lives again.

For example, if there is a chore to be done, memory of how the deceased did this chore is likely to be easily accessible. This is useful for the bereaved person, who can then consider whether this would be a good way to do it or not. If not, it will help to see why not. If there is no idea how the person actually did the chore, easily accessible memories might still make it possible to recall what advice the deceased might have provided. Many people make it a habit to “talk” to a loved one who has died, especially when they are solving a problem or making an important decision.

Dr Pies: What about complicated grief, Kathy? What context does that occur in?

Dr Shear: Sometimes, maladaptive feelings, thoughts, or behaviors can get a foothold during grief. A person might become caught up in troubling thoughts about the circumstances or consequences of the death, or about aspects of their relationship with the deceased. Sometimes, reminders of the loss are so painful that the bereaved person goes to great length to avoid these, and thoughts about the death are so intensely painful that it is difficult to reflect on it and make peace with the loss. Or there may be an external situation: hostility or severe neglect by other people, devastating financial consequences, or other highly stressful changes in a bereaved person’s situation.

Complicated grief occurs when something interferes with learning that is the core process of healing. The result is a situation in which the bereaved person seems “stuck” in acute grief, trying to deal with the complications that block acceptance and adaptation to the loss. Initially identified using a 19-item self-report questionnaire called the Inventory of Complicated Grief, complicated grief can be a disabling problem. Complicated grief is best understood as a severe form of grief, similar in many respects to the experience almost everyone has when a loved one dies.

Bereavement Doesn’t “Immunize” Against Depression

Dr Pies: Thanks to you both for these excellent descriptions.

One of the most controversial decisions the DSM-5 made was to drop the so-called “bereavement exclusion” when diagnosing an MDE. Essentially, the DSM-IV had instructed clinicians not to diagnose major depression within the first 2 months after the death of a loved one, unless certain putative markers of severity were present, such as suicidal ideation, marked functional impairment, psychomotor retardation, sense of worthlessness, or psychosis.

The DSM-5, in contrast, tells us that the subset of persons who meet the full symptom/duration/severity criteria for major depression within the first few weeks after bereavement should not be excluded from the set of all persons with major depression.To put it more simply: The DSM-5 recognizes that bereavement does not “immunize” the grieving person from major depression, and is in fact a frequent precipitant of major depression.[6]

Despite some guidance in the DSM-5 regarding the differences between grief and major depression, many clinicians remain puzzled or uncertain as to how the two are distinguished.

Sid, this is an area you have explored deeply. Can you give the primary practice physician, and psychiatrists as well, four or five key features that you look for when distinguishing grief from major depression, in the context of recent bereavement? And, then, Kathy, can you add a bit on how complicated grief differs from major depression?

Dr Zisook: The first step is to remember precisely what grief and major MDD represent. The death of a loved one almost always triggers grief; but, an exquisitely stressful and sometimes traumatic life eventmay also precipitate a number of adverse health consequences, including (but not limited to) MDD.

Grief is the normal, expected, generally adaptive psychological, biological, interpersonal, and social response to loss. MDD, on the other hand, is a serious, sometimes malignant, life-threatening, mental disorder marked by intense, persistent and pervasive sadness or anhedonia. MDD generally is a recurrent condition and often is quite chronic.

Thus, I would rephrase the question I was asked to discuss. The more meaningful question is not so much, “How can grief and MDD be differentiated?” as it is, “How can an MDE be diagnosed when it occurs in a recently bereaved person who is still actively grieving?” That can be a challenging and tricky clinical conundrum, even for the most experienced clinician.

The DSM-5 does a good job in helping clinicians to understand when grief may be complicated by a co-occurring MDE. In the footnote for the diagnostic criteria of an MDD, the DSM-5 notes:

Key issue: The predominant affect in grief that is not complicated by an MDE a sense of emptiness and loss. When there is also an MDE, persistent and pervasive depressed mood and the inability to anticipate happiness or pleasure predominate, even in the absence of reference to the deceased.

Nature of dysphoria: In grief that is not complicated by an MDE, the dysphoria tends to decrease in intensity over days to weeks and occurs in waves that are associated with thoughts or reminders of the deceased—so-called “pangs of grief.” When an MDE intervenes, the dysphoria tends to be more persistent and not tied to specific thoughts or preoccupations.

Positive emotions: In grief, the pain may be accompanied by positive emotions, such as humor, relief, warmth, and even pleasure in the closeness with significant others. In contrast, when a MDE also is present, more pervasive unhappiness and misery are likely to leave no room for warmth, joy, or humor.

Preoccupations: Thoughts and memories of the deceased predominate in grief. When the grief is accompanied by a coexisting MDE, thoughts also are focused on oneself being bad, undeserving, or unworthy.

Self-esteem: In grief, self-esteem is generally preserved. When grief is accompanied by an MDE, thoughts of worthlessness and self-loathing also are common.

Consolability: Grieving individuals often feel supported and comforted by friends and relatives sharing time and conveying condolences. When an MDE intervenes, people are far less consolable or approachable.

Suicidal thoughts: In grief, thoughts of death or dying are generally focused on the deceased and possibly about joining them. In a bereaved person who is also suffering from an MDE, thoughts may be more focused on ending one’s life because of feeling undeserving of life, feeling unable to withstand the seemingly unending torture of depression, and/or mistakenly believing that others would be better off without them.

Even with these guidelines, is not always easy to diagnose an MDE in the context of bereavement. It is clear that a symptom checklist is not enough. Rather, a more nuanced assessment, taking into accountsome of the features and phenomenology noted above, combined with the unique history, beliefs, and social/cultural dimensions of the person and their environment, must be weighed into the diagnostic process.

Sometimes it is useful to wait before making a definitive diagnosis. This is especially true in someone who does not have a previous history of MDD, and if symptoms are relatively mild and not life-threatening. When in doubt, past history and family history, as well as a tincture of time, may help inform clinical judgment and decisions.

More on Parsing Complicated Grief and MDD

Dr Pies: That’s extremely helpful, Sid, and you remind us once again that grief and major depression are not mutually exclusive—that one can be grieving a death and also be experiencing an MDE.

Kathy, how about your take on what differentiates complicated grief from major depression?

Dr Shear: Complicated grief is at the high end of the grief spectrum in both intensity and duration. People with complicated grief are often caught up in ruminations, avoidance, or maladaptive proximity-seeking. Complicated grief ruminations are usually focused on counterfactual accounts of the death—for example, “If only I had made him go to the doctor sooner” or “If only I had not left the room right before she died.”

Depressive rumination is different. Depressed people get caught up in thoughts about being worthless or being a bad person or thoughts that nothing good ever happens in the world, etc. With depression, people may become withdrawn and not want to go out or socialize.

With complicated grief, avoidance is more specific, focused on not wanting to confront reminders of the person who died. People with complicated grief are desperate to feel close to their deceased loved one and may spend hours looking at photos, touching or smelling their clothes, or daydreaming about times they were together. These times are usually pleasurable until the person “wakes up” and remembers that the person is gone.

World Health Organization Guidelines for Management of Acute Stress, PTSD, and Bereavement: Key Challenges on the Road Ahead


Summary Points

  • The implementation of new WHO mental health guidelines for conditions and disorders specifically related to stress is likely to face obstacles, particularly in low- and middle-income countries.
  • Formulation of evidence-based guidelines is complicated by limited knowledge regarding (a) the effectiveness of commonly implemented interventions, (b) the effectiveness of established evidence-based interventions when used in situations of ongoing adversity, and (c) the effectiveness of widely used cultural practices in LMICs. The application of the guidelines requires improved knowledge on how to reduce potentially harmful practices that are widely applied.
  • The implementation of recommendations regarding psychotherapeutic interventions will require an approach that balances (a) strengthening the availability and capacity of specialists to train and supervise and (b) shifting to the delivery of psychotherapy by non-specialists.
  • The strengthening of evidence for managing these conditions will require collaborative efforts by researchers and practitioners in a manner that is mindful of local sociocultural and health system realities.

Why New Guidelines on Mental Health Conditions Specifically Related to Stress?

In 2009, the World Health Organization (WHO) launched the Mental Health Gap Action Programme (mhGAP), which has since been used in more than 50 countries worldwide. The mhGAP is aimed at improving access to evidence-based mental health interventions, by ensuring their integration within non-specialized (primary care) settings, the emphasis being on low- and middle-income countries (LMICs). The evidence-based guidelines formed the basis for the development of the mhGAP Intervention Guide [1].

Since then, WHO has been asked repeatedly to provide similar guidelines as a basis for an additional Intervention Guide Module, for conditions specifically associated with major stressors such as potentially traumatic events (e.g., involvement in severe accidents, armed conflicts, gender-based violence) and major losses (e.g., bereavement, displacement). Exposure to such major stressors is common in many LMICs [2].

The approach adopted by WHO was to ensure a comprehensive focus in developing guidelines for adults, children, and adolescents, comprising recommendations on pharmacological and psychological interventions. The guidelines include but extend beyond posttraumatic stress disorder (PTSD) to a range of conditions that are relevant to non-specialized health settings, including symptoms in the first month after exposure (acute traumatic stress symptoms, insomnia, enuresis, dissociation, and hyperventilation); PTSD; and bereavement in the absence of frank mental disorder. The development [3],[4] and content [5] of the evidence-based recommendations and resulting intervention module are described in more detail elsewhere. A brief summary of the recommendations is provided in Table 1.

thumbnail

Table 1. Overview of recommendations.

doi:10.1371/journal.pmed.1001769.t001

Although these guidelines and companion intervention guide are an important first step, their success will rest on their actual implementation in settings with high needs for mental health care. In this paper, we discuss challenges encountered in the formulation of guidelines, as well as potential obstacles that may constrain effective implementation of these guidelines in low-resource settings. We also offer suggestions for how these obstacles may be overcome. The authors represent the Guideline Development Group (JB, JC, ZH, JTVMdJ, OO, SS, DS, RS, AS, LV, IW, DZ), WHO secretariat (MvO), and four consultants to the guideline development process (WAT, CB, LJ, NM).

What Are the Key Obstacles on the Road Ahead?

First, the Guideline Development Group (GDG) (see author contributions) discovered that there is a dearth of scientifically rigorous research supporting many of the most commonly used interventions for managing conditions specifically associated with stress. To establish the evidence, the GDG identified recent systematic reviews, or they commissioned reviews in cases for which none were available. The evidence is particularly poor for children and adolescents: for three out of 11 questions asked, no specific recommendations could be made based on existing evidence. In relation to the absence of evidence in general, a notable example in adults concerns symptoms manifesting in the first month after exposure to major stressors. At the outset, the GDG commissioned evidence searches for a broader set of psychological interventions to manage acute traumatic stress symptoms in adults, including problem-solving counseling, relaxation, and psycho-education. However, it was deemed that there was insufficient evidence to recommend either in favor or against the use of these interventions. In humanitarian settings in LMICs specifically, earlier systematic reviews have shown that there is a wide gap between interventions that are commonly implemented and evidence for interventions in such settings [6].

Second, a key challenge is the limited availability of mental health resources in LMICs in general, creating a major obstacle to implementation of new mental health recommendations. Lack of resources takes a number of forms, including limits in basic mental health infrastructure, budget, and personnel, particularly in humanitarian settings [7]. Mental health is often a low priority for governments and donors, and too often there is a lack of political will to prioritize this area [8]. Where basic mental health resources do exist, there is a lack of specialized staff to provide the necessary training and supervision to ensure recommended psychotherapeutic interventions such as cognitive behavioral therapy (CBT) and eye movement desensitization and reprocessing (EMDR) can be implemented [9]. There is promising evidence, however, based on randomized controlled trials, that non-specialists (for example, community health workers or personnel without a formal mental health background working for non-governmental organizations) can successfully deliver psychotherapeutic interventions based on a task-sharing approach [10][12]. Nevertheless, it is uncertain whether psychotherapeutic interventions can be feasibly scaled up and sustained in naturalistic settings that lack the financial resources (e.g., for supervision) which were available to researchers when these interventions were tested.

Third, some practitioners may be reluctant to adhere to recommendations that caution against practices that are widely applied. These include, for example, recommendations not to offer benzodiazepines for acute traumatic stress symptoms, nor to offer structured psychological interventions for bereavement reactions in the absence of frank mental disorder. Studies have revealed the over-prescription of benzodiazepines in some LMIC health care settings [13],[14], supporting general impressions that in humanitarian settings the prescription of benzodiazepines for symptoms of acute stress (including insomnia) and bereavement is commonplace. Similarly, grief counseling is a popular intervention following bereavement in spite of the lack of evidence that it is necessary or effective [15]. Overall, there may be major challenges in achieving changes in practice in low-resource settings where the evidence-based alternative suggests more time-intensive management strategies or where expectations of help-seekers favor pharmacological management, as is common in many LMICs.

Fourth, mhGAP recommendations are based on evidence gathered mainly in well-resourced health settings in industrialized countries. There is uncertainty as to what extent the findings can be generalized across diverse sociocultural settings. Furthermore, there is a paucity of evidence concerning the effectiveness of (a) interventions for specific cultural idioms or concepts of distress [16] and (b) existing supportive cultural practices to manage stress-related conditions, such as yoga for stress management, or cultural mourning practices for bereavement. This is a paradox because international consensus guidelines for mental health and psychosocial interventions in humanitarian emergencies explicitly recommend identifying and building on such practices where possible [17], the evident advantages being accessibility, acceptability, and sustainability.

Fifth, a number of peer reviewers and the GDG raised questions about the specific challenges of providing effective treatments in contexts where stressors are ongoing. Situations of ongoing adversity, such as in the context of armed conflict, chronic poverty, or intimate partner violence, raise two important questions: (1) whether to prioritize social interventions over psychotherapeutic interventions in this population [18] and (2) if treatments are equally effective and safe for those exposed to ongoing major stressors. Limited knowledge is available to guide decisions on both issues. With regard to the first question, consensus guidelines have recommended addressing social and psychological issues simultaneously in a multilayered, multisectoral approach. However, randomized trials have not yet indicated whether this is more effective than single-intervention approaches. With regard to the second question, there is some evidence that treatments can be effective in situations of ongoing adversity [19],[20], whereas other studies have shown reduced treatment benefits for populations facing chronic adversity [21].

How Can These Obstacles Be Overcome?

First, concerted action is needed to strengthen the evidence base for interventions. This will require testing the efficacy of treatments for conditions specifically related to stress that previously have proven efficacious, generally in high-income countries. Also, it will require determining the efficacy of interventions that are currently very popular in practice but have not been rigorously studied. Currently popular interventions include non-specific counseling, psycho-education, structured recreational and sports activities, and provision of child-friendly spaces. In relation to the current knowledge base, there are both consistent and inconsistent findings [22]. For example, amongst children and adolescents with PTSD, CBT has been shown to be more effective than supportive counseling for a range of outcomes [23]. In humanitarian settings, some studies have shown benefits of counseling [24],[25], whereas others have not [26][28]. It is challenging to make broad conclusions based on existing studies given the heterogeneity of counseling approaches applied, and further rigorous research is required. Child-friendly spaces provide an additional example. This popular intervention aims at promoting and supporting resilience and well-being amongst children and young people who have recently experienced natural or human-made disasters by provision of community-organized, structured activities conducted in a safe, child-friendly, and stimulating environment. A recent systematic review found no randomized controlled trials evaluating this methodology, and only one study applying a comparison group with pre- and post-intervention measurement of outcomes [29].

The evidence base could benefit from action on two fronts: supporting research efforts in LMICs, as well as building the capacity of agencies to measure the outcomes of interventions in the course of program implementation. Research capacity building in LMICs could assist in initiating research projects that are relevant to low-resource settings, e.g., testing culturally congruent approaches for stress management. A recent initiative to set research priorities for mental health and psychosocial support in humanitarian settings, in which there was strong representation from personnel working in LMICs, produced a largely practice-informed research agenda; notably, there was little focus on topics that have dominated debates in the peer-reviewed literature. For example, the agenda focused on a range of disorders and conditions besides PTSD, in spite of the latter diagnosis being the subject of most attention in the literature [30]. Building research capacity within agencies implementing interventions (e.g., government and non-governmental organizations) has the potential to improve knowledge on a larger scale and in a shorter time frame. For example, including outcome indicators measuring mental health as a standard monitoring practice could assist in rapidly identifying which practice elements are associated with positive changes. Finally, future research efforts should take costs of treatments into account to better inform policy and practice.

Second, the limited availability of mental health resources in LMICs will need to be addressed for successful implementation of these guidelines. For example, building the capacity to train and supervise psychotherapeutic interventions in non-specialist settings will be crucial to ensure that such services are sustainable and of sufficient quality [31]. This is likely to require a balanced approach in building capacity of both specialist supervisors and non-specialist health workers in community and primary health care settings [32]. Future studies could explore implementing and evaluating stepped care models in which (a) those who are in greatest need receive timely interventions, (b) people are identified and receive interventions initially from community workers, and (c) those people are referred to progressively more resource-intensive interventions, depending on their response to first-line treatments [33]. In addition, a promising direction concerns transdiagnostic approaches in which mental health practitioners learn skills across a variety of therapies to address a range of common mental disorders [34]. This approach seems most desirable given the high levels of comorbidity (for example, involving PTSD, anxiety, and depression) in the context of major stressors, and the lack of feasibility of training personnel in numerous separate interventions that address single conditions.

Third, if the aim is to ensure that negative recommendations are implemented (that is, to discontinue established practices) it is important to understand (a) the reasons behind practitioners’ current use of contra-indicated interventions, (b) barriers to using evidence-based approaches, and (c) strategies that will encourage practitioners to take up evidence-based alternatives. Such research falls within the scope of dissemination and implementation science, a field of research that has not yet received sufficient attention for mental health interventions in LMICs [35]. For example, important research questions in this regard may include the following: What are the most important determinants of currently employed pharmacological and non-pharmacological interventions (e.g., demand-side preferences of clients versus delivery-side training and preferences of mental health workers)? What are the perspectives of mental health professionals in LMICs with regard to evidence-based approaches that often originate in high-income countries? What are key barriers and facilitators for implementation and scaling up of evidence-based interventions? What types of adaptations are necessary for evidence-based interventions to be compelling and practical from a contextual and cultural perspective? The limited available research on uptake of guidelines by practitioners has shown that it is critical to fit guidelines to local contexts, to make recommendations sensitive to how work is organized locally, and to ensure feedback mechanisms to monitor implementation of recommendations [36],[37].

Fourth, lack of knowledge with regard to cultural concepts of distress and the effectiveness of existing cultural practices need to be addressed. This will require a willingness to take seriously local perspectives on mental health across highly diverse sociocultural settings in LMICs. Such efforts would benefit from multidisciplinary collaboration, in which experts in qualitative research (e.g., to identify the phenomenology of cultural concepts of distress, views on determinants of these concepts, and help-seeking patterns) join hands with experts in quantitative research (e.g., to identify prevalence rates and establish efficacy of interventions). A recent meta-analysis found a particularly high level of overlap between locally defined cultural concepts of distress and a diagnosis of PTSD. However, one of the major shortcomings of this literature concerned the failure to include cultural concepts of distress in treatment outcome studies [16].

Finally, implementation efforts need to be more responsive to the reality that populations affected by humanitarian crises in LMICs commonly are living in settings of ongoing exposure to major stressors. Further research needs to confirm whether evidence-based treatments can be safely and sustainably implemented in low-resource settings with populations exposed to high levels of ongoing adversity and to identify additional promising intervention approaches. Clinical interventions are only part of the picture, given the impact of social and economic factors on mental health in these settings. There is a need to strengthen preventive approaches that address the major social determinants of mental health, including poverty, gender-based violence, and social exclusion [38]. One approach would be to combine preventive and treatment interventions—in a way, to simultaneously target the causes and consequences of adversity, thereby addressing both ends of a vicious cycle. For example, an intervention that would relieve symptoms of mental disorders in women exposed to past intimate partner violence could, at the same time, aim at empowerment of women to prevent future violence, engagement of men, and awareness-raising in the community as a whole about the deleterious effects of domestic violence. Previous research has indicated that psychotherapeutic treatments by themselves may lower chances for future victimization [39].

In conclusion, although the new WHO recommendations on conditions specifically related to stress present an important step forward, there will be many challenges in implementation. The road ahead is to address these challenges through concerted and multidisciplinary efforts by policy makers, practitioners, and researchers.

Cashew nut by-product may help cut sleeping sickness .


A new method for making chemicals that lure tsetse flies to traps has been developed. It uses a cheap by-product from the cashew nut industry as its starting material, so the discovery may mean the flies — which carry sleeping sickness (also known as African trypanosomiasis) — can be trapped at a lower cost.

The method, published in Green Chemistry last month, could offer a sustainable and more-affordable way to make two ‘attractant’ chemicals: 3-ethylphenol and 3-propylphenol.

Many existing odour attractants are prohibitively expensive and not widely available in large quantities. It is possible to use buffalo urine, which naturally contains chemicals that attract the flies, as a substitute — though this has the downside of smelling rather unpleasant.

Because the new method produces the attractants from cashew nut oil starting material, it may mean African countries could produce the chemicals locally. Cashew nut producers, which are widespread in Sub-Saharan African countries including Côte d’Ivoire, Nigeria and Tanzania, generate more than 300,000 tonnes of this waste product every year.

The liquid contains the chemical cardanol, which can be used to make both 3-propylphenol and 3-ethylphenol, through chemical processes developed by Lukas Goossen, a chemist at the University of Kaiserslautern in Germany who jointly led the research.

David Cole-Hamilton, a chemist at the University of St Andrews, United Kingdom, who also led the research, tells SciDev.Net that the resulting attractant can be coated on a plastic sheet or similar surface, along with an ordinary insecticide. “The attractant lures the insects to the sheet where they are poisoned,” he says.

Cole-Hamilton says the team was anxious to avoid using farmland to produce the raw materials for chemical production. This would put effectively food production and insect control in competition. “For this reason, we targeted waste products from food or other production processes,” he says.

The new process to make the attractants from cashew nut liquid is cheaper than existing methods using synthetic compounds. Yet it involves using small quantities of an expensive Palladium-based catalyst, so it the attractants would still end up too expensive for most individuals to buy, Cole Hamilton thinks.

“A whole village might be able to [collectively buy them], particularly if there were a government or international subsidy,” he says.

However, there may be a solution to this problem, he says. One other product from the process his team has developed is 1-octene, a chemical used to make polythene. “World demand for 1-octene is 600,000 tonnes [a year] and it sells at US$2 per kilogram so the profit from this product could be used to reduce the cost of the attractant,” he says.

Andrew Jonathan Nok, a biochemist at Ahmadu Bello University, Nigeria, and one of the country’s leading sleeping sickness researchers, says the work is commendable.

But, he adds, that advances in trapping flies are unlikely to lead to the elimination of sleeping sickness in themselves because tsetse flies may learn to ignore the attractants.

Nok believes drug and vaccine development remain the best paths for tackling the disease. – See more at: http://www.scidev.net/global/disease/news/cashew-nut-sleeping-sickness.html#sthash.TkRs8JcE.dpuf

Clove Bud Oil: The Plant-Based Dental Aide


You’re probably familiar with clove, an aromatic spice that is commonly used in Indian and Chinese culture as seasoning and for medicinal purposes. Cloves, also known as clove buds, gained popularity all over the world, especially in the western hemisphere, during the 7th century because of their health benefits.

Like other spices, cloves can also be used to make an essential oil. While it is not as popular as other plant oils, there are numerous reasons why you should consider having clove bud oil at home.

What Is Clove Bud Oil?

Clove bud oil is derived from the clove tree, a member of the Myrtaceae family. This tree is native to Southeast Asian countries like Indonesia. From the evergreen, you can derive three types of clove essential oils: clove bud oil, clove leaf oil, and clove stem oil.

Out of the three, clove bud essential oil – also known as Eugenia carophyllata – is the most popular in aromatherapy. Oil produced from the leaves and stems have stronger chemical compositions and can easily cause skin irritations, which makes them unfit for aromatherapy.1

During the time of ancient Greeks and Romans, this plant oil was used to relieve toothaches and to combat bad breath.2 Its presence was also found in Chinese and Ayurvedic medicine with the same purpose.

Today, clove bud oil is known for its benefits to oral health.3 This essential oil has been approved as a dental anesthetic and, as mouthwash and gargle, can help relieve toothaches, as well as fight mouth and throat infections. It is also added to pharmaceutical and dental products.

Uses of Clove Bud Oil

The oil of clove buds is known for its antimicrobial, antifungal, antiseptic, antiviral, aphrodisiac, and stimulant properties. Apart from its positive effects in the field of dental care, it can also be used as a treatment for minor health concerns. Below are some of the most common uses of this plant oil:4, 5, 6

  • Digestive aid – Cloves possess beneficial properties that help relax the smooth muscle lining in your gastrointestinal tract. When used as an oil, it can aid in halting digestive problems, like nausea and vomiting.
  • Skin care product – When applied topically, clove buds can help address skin problems like warts, acne, sagging skin, and wrinkles.
  • Insect repellent – When used together with citrus essential oils, this plant oil can help ward insects away.
  • Expectorant – Clove bud oil is also used to help ease respiratory problems, such as cough, colds, sinusitis, asthma, and tuberculosis. In fact, chewing on a clove bud is said to help sore throats.
  • Antiseptic – It is applied topically  to address fungal infections, wounds, and cuts. It is also a common treatment for athlete’s foot.
  • Perfume ingredient – Bud oil, with its strong and unique scent, is used in carnation, rose, and honeysuckle perfumes. It has a strong and unique scent.
  • Flavoring agent – This is because of the oil’s unique flavor and aroma.
  • Soap ingredient – Clove bud oil is used in soaps not just for its fragrance, but also because of its relaxing and antiseptic qualities.
  • Massage oil – It can be used to relieve pain and stress.

Composition of Clove Bud Oil

The predominant chemical constituents found in all three types of clove oils are eugenol, eugenyl acetate, and caryophyllene. However, these three types all vary in their eugenol content. For instance, clove leaf oil contains very low levels of eugenol, compared to clove bud oil. Oil derived from the clove stem contains the highest amount of the compound, which makes it unsuitable for external applications.

Benefits of Clove Bud Oil

clove bud oil benefitsClove oil owes much of its health benefits to eugenol,7 which make up to 90 percent of the oil. This compound provides potent antiseptic and anti-inflammatory benefits, and is also responsible for preventing cloves from spoiling.

Thanks to this chemical compound, this plant oil is very effective against dental pain, sore gums, mouth ulcers, cavities, and bad breath. It is because of the compound that clove oil, as well as other spice oils that contain eugenol (like cinnamon, basil, and nutmeg oils), are added to dental products, insect repellents, perfumes, foods, and even pharmaceutical products.

Eugenol also causes clove oil to have stimulating and warming properties, which make it a popular choice among aromatherapy practitioners. Part of its list of benefits is its ability to stimulate your metabolism by helping improve your blood circulation and lowering your body temperature. It can also contribute to your digestive health and address problems like hiccups, indigestion, motion sickness, and excess gas.

Apart from helping support your metabolism, clove bud oil can also help relieve stress and help lessen mental exhaustion. Some use it to tackle neural health problems, such as depression and anxiety. The oil can also work as an aphrodisiac and treatment for insomnia.

 Make Clove Bud Oil

Clove bud essential oil, including the other two forms of clove oil, is produced by steam distillation. However, you can also extract oil from clove buds at home.  Here’s an easy-to-follow guide from eHow.com:8

What You’ll Need

  • 4 fresh clove buds, crushed
  • 600 ML airtight bottleneck jar
  • Carrier oil, like olive oil

JIA Still Needs Predictive Tools for Methotrexate Response


For now, the field has Interesting but unvalidated candidates.

Predictors for the efficacy of methotrexate, and any potential drug-related adverse events, in juvenile idiopathic arthritis (JIA) exist, but they still require validation, according to a literature review.

Based on an evaluation of 20 quality original articles and three literature reviews, potential but unvalidated baseline predictors of efficacy within 6 months of starting methotrexate included antinuclear antibody positivity, a higher Childhood Health Assessment Questionnaire score, myeloid-related protein 8/14 level, long-chain MTX polyglutamates, and involvement of both wrists, reported E.H. Pieter van Dijkhuizen, MD, of University Medical Center Utrecht in the Netherlands.

For methotrexate adverse events, potential — but still unvalidated — predictors were alanine aminotransferase and thrombocyte level, and two single nucleotide polymorphisms (SNPs) in the gamma-glutamyl hydrolase and methylenetetrahydrofolate reductase genes, they wrote in Pediatric Rheumatology.

For more than 25 years, methotrexate has been the inexpensive cornerstone of disease-modifying antirheumatic drug (DMARD) therapy in JIA, but response has been unpredictable, and methotrexate is ineffective in about 30% of patients. In order to start patients early on joint-preserving treatment, it is crucial to know beforehand which patients will respond well to methotrexate and which should receive early intervention with a biologic, the authors explained.

It is also important to know which patients are at greater risk for adverse events since methotrexate can cause gastrointestinal (GI) side effects, transient elevation of liver enzymes, and possibly cytopenias, along with negative consequences for quality of life and compliance.

The 20 studies, done in Europe, the U.K., Japan, and the U.S., were a mix of retrospective, prospective, retrospective-prospective, and cross-sectional. Fifteen assessed the efficacy of methotrexate treatment, commenced within a median of 1.5 years from disease onset, and outcomes were most often assessed according to the American College of Rheumatology response criteria. Follow-up was typically short, ranging from 6 months to 1 year but extending to 7.3 years in one study.

On the genetic front, possible predictors involved the methotrexate metabolic pathway via SNPs in the adenosine triphosphate binding cassette and the solute carrier transporter gene families. The pro-inflammatory molecule osteopontin and hemoglobin levels might also identify probable responders, the authors stated.

They found that neither demographic variables nor categories of JIA were predictive in most studies. Disease activity parameter also was not predictive, but the physician’s Global Assessment was a possible predictor.

“The involvement of individual joints was assessed in too few studies to be conclusive, but bilateral wrist involvement was a potential predictor,” the authors wrote.

Adverse events associated with methotrexate, assessed by seven of the studies, ranged from overall adverse events to single adverse events, such as liver toxicity, GI complaints, or intolerance measured by the Methotrexate Severity Score. Follow-up ranged from 6 months to a mean of 58.2 months. No study focused on serious infections.

The polyarticular categories could also potentially pose a risk for methotrexate side effects, the authors suggested.

“Overall, no unequivocal predictive single nucleotide polymorphism has been found yet, because many were assessed in only one study, or were predictive in one study and showed no effect in others,” the researchers wrote. They added that gene regions associated in the genome-wide association study also looked promising for prediction.

The authors urged the creation of a reliable clinical prediction model and the continued investigation of other predictors.

REPORT ON REMISSION IN PATIENTS WITH MS THREE YEARS AFTER STEM CELL TRANSPLANT


stem-cell-163711_1280
Three years after a small number of patients with multiple sclerosis (MS) were treated with high-dose immunosuppressive therapy (HDIT) and then transplanted with their own hematopoietic stem cells, most of the patients sustained remission of active relapsing-remitting MS (RRMS) and had improvements in neurological function, according to a study published online by JAMA Neurology.

MS is a degenerative disease and most patients with RRMS who received disease-modifying therapies experience breakthrough disease. Autologous (using a patient’s own cells) hematopoietic cell transplant (HCT) has been studied in MS with the goal of removing disease-causing immune cells and resetting the immune system, according to the study background.

The Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) study examines the effectiveness of early intervention with HDIT/HCT for patients with RRMS and breakthrough disease. The article by Richard A. Nash, M.D., of the Colorado Blood Cancer Institute at Presbyterian/St. Luke’s Medical Center, Denver, and coauthors reports on the safety, efficacy and sustainability of MS disease stabilization though three years after the procedures. Patients were evaluated through five years.

Study results indicate that of the 24 patients who received HDIT/HCT, the overall rate of event-free survival was 78.4 percent at three years, which was defined as survival without death or disease from a loss of neurologic function, clinical relapse or new lesions observed on imaging. Progression-free survival and clinical relapse-free survival were 90.9 percent and 86.3 percent, respectively, at three years. The authors note that adverse events were consistent with the expected toxic effect of HDIT/HCT and that no acute treatment-related neurologic adverse events were seen. Improvements in neurologic disability, quality-of-life and functional scores also were noted.

“In the present study, HDIT/HCT induced remission of MS disease activity up to three years in most participants. It may therefore represent a potential therapeutic option for patients with MS in whom conventional immunotherapy fails, as well as for other severe immune-mediated diseases of the central nervous system. Most early toxic effects were hematologic and gastrointestinal and were expected and reversible. Longer follow-up is needed to determine the durability of the response,” the authors conclude.

LYME DISEASE ENHANCES SPREAD OF EMERGING TICK INFECTION


141229164848-large
Mice that are already infected with the pathogen that causes Lyme disease appear to facilitate the spread of a lesser-known but emerging disease, babesiosis, into new areas.

Research led by the Yale School of Public Health and published Dec. 29 in the journal PLOS ONEused laboratory experiments, mathematical models, and fieldwork data to find that mice infected with the agent that causes Lyme disease (Borrelia burgdorferi) are at increased risk for also transmitting Babesia microti, the pathogen responsible for babesiosis, and could be enhancing the geographic spread of this emerging disease. Both diseases are transmitted to humans through the bite of infected black-legged ticks (Ixodes scapularis).

The finding provides a possible answer as to why human babesiosis is only emerging in areas where Lyme disease is well established, said Maria Diuk-Wasser, senior author of the study, who performed the research in collaboration with Peter Krause’s and Durland Fish’s research groups while she was assistant professor at the Yale School of Public Health. Diuk-Wasser, who maintains an adjunct position and active collaboration with the Yale School of Public Health, is an associate professor at Columbia University. Other study collaborators were at the Yale School of Medicine, Tufts Medical Center, and the Royal Melbourne Institute of Technology.

“Ticks and natural hosts are commonly co-infected in nature, so understanding how these pathogens may influence each other’s abundance and distribution is key for public health,” Diuk-Wasser said. “We found that B. burgdorferi and B. microti co-occur in ticks more frequently than expected, resulting in enhanced human exposure to multiple infections that can cause more severe symptoms and sometimes make diagnosis more difficult.”

Ninety-five percent of all Lyme disease cases are reported from 14 states (primarily on the East Coast and in the Midwest), and there are approximately 30,000 new cases reported each year. Babesiosis is found in similar regions, but 95% of cases are concentrated in the seven “core” Lyme disease states (Connecticut, Massachusetts, New Jersey, New York, Rhode Island, Minnesota, and Wisconsin). About 1,000 new cases of babesiosis are reported annually.

While the two diseases share some of the same symptoms, babesiosis is potentially fatal in immunocompromised patients and can be transmitted through blood transfusions in addition to tick bites, posing an additional public health threat.

Refined mathematical models may allow scientists to better predict areas that are at risk for B. microti expansion and to assess whether methods to reduce B. burgdorferi infection in ticks and mice may simultaneously reduce B. microti infection, Diuk-Wasser said.